FDA Cancer Drug IND Exemptions Clarified In Draft Guidance
Executive Summary
FDA is seeking to reduce the number of unnecessary IND submissions it receives by issuing a draft guidance clarifying IND exemptions for oncologic products
You may also be interested in...
IND Exemptions For Cancer Trials To Be Based On Risk, Not Just Size
FDA has revised its guidance on IND exemptions for marketed cancer drugs to allow some large randomized trials to qualify
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011